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were clearly judged favourable or unfavourable. In decisions where the evidence
was rated uncertain or was not assessed, we found that the number of stakeholders
participating in the voting stage (odds ratio2.52; p0.03) and the scientific rigour
in assessment of costs/cost-effectiveness (OR6.25; p0.06) increased the likeli-
hood of a positive decision outcome. On the contrary, it significantly decreased for
prescribed medicines (OR0.05; p0.003). CONCLUSIONS: Despite claims for mak-
ing transparent and participative coverage decisions, the phase of evidence gener-
ation and synthesis is most critical for technology appraisal. Decison makers usu-
ally adapt the assessment recommendations. Decision outcomes seem to a large
extent independent of how processes are configured.
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OBJECTIVES: Community-acquired pneumococcal pneumonia is an important
cause of hospitalization and death among adults, but figures on the prevalence of
Streptococcus pneumoniae largely vary. We aimed to identify the prevalence of Strep-
tococcus pneumoniae by systematically reviewing all available etiological studies of
adult patients with community-acquired pneumonia (CAP) over the period January
1990- November 2011 across European countries. METHODS: Two reviewers con-
ducted a systematic literature search using PubMed of English-language articles on
the prevalence of adult CAP caused by S. Pneumoniae and manually reviewed the
article bibliographies. A mixed-effects meta-regression model was developed and
populated with 24,236 patients obtained from 79 articles that met in- and exclusion
criteria. The meta-regression was adjusted for country and region characteristics
as well as other possible independent covariates. RESULTS: The findings from the
mixed-effects meta-regression model indicate that the observed prevalence of S.
pneumoniae in CAP significantly differs between European regions even after ad-
justing for various covariates including patient characteristics, diagnostic tests,
antibiotic resistance and health-care setting. Performing a diagnostic PCR assay
increased the probability of detecting S. pneumoniae substantially, compared to all
other diagnostic tests included. Furthermore, S. pneumoniae was more likely to be
confirmed as the cause of a CAP in cases treated in the ICU as compared to those
treated in the hospital or in the community. CONCLUSIONS: This study provides
estimates of the prevalence of S. Pneumoniae in CAP, independent of study design,
or other risk factors, which could be used for predictions of the health and eco-
nomic impact of adult pneumococcal vaccination.
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OBJECTIVE: A fundamental information needed to conduct economic evaluations
of vaccines is effectiveness against disease. However, effectiveness is not always
observed directly and relies on an immunological response that predicts protec-
tion. Typical immune responses which are predictive of protection are neutralizing
antibodies, called surrogates or correlates of protection (COP). Often the COP is
reduced to a threshold value that differentiates between protected and susceptible.
COPs are relied on in place of estimates of effectiveness and for immunization
policy, however there are no consistent criteria or statistical methods for establish-
ing candidate immune response as predictive COP. Our aims were to review pro-
posed hierarchies of evidence necessary to establish a COP and statistical methods
used to relate immune responses to protection. METHODS: The strength of evi-
dence for demonstrating a COP based on different frameworks and early and mod-
ern statistical methods approaches to establish a COP were reviewed. Findings and
Recommendations: Different frameworks define different levels of confidence in
COPs. The Prentice framework is significance testing-driven and requires protec-
tion to be related to vaccination, the correlate related to the vaccine and correlate
related to clinical endpoint. Moreover vaccination should not add additional infor-
mation on protection over that explained by the correlate. A framework by Qin
proposes levels of evidence based on single or multiple randomized trials. To esti-
mate thresholds, early vaccine studies relied on inspection of disease rates ob-
served in discrete intervals of assay values. Modern examples employed Chang-
Kohberger method, but this requires an estimate of vaccine efficacy based on
occurrence of disease before it can be used. The scaled-logit model permits esti-
mation of continuous protection curves by antibody titer. In addition to statistical
criteria, other considerations include clear endpoint definition, laboratory assays,
host and population factors. New statistical methods should be developed and
tested within evidence frameworks to better obtain estimates of vaccine effective-
ness.
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OBJECTIVES: Influenza is a disease that occurs every year for a few months in
winter season. Predictions on vaccination strategies require a deep understanding
of current influenza epidemics. The aim of this work is the reproduction of a past
influenza season through a model, its examination and to make its dynamics
transparent. METHODS: We used an agent based epidemic model to simulate the
spread of influenza. It belongs to the class of dynamic transmission models and
simulates single persons with individual behavior who live in an environment,
meet each other and spread the virus from person to person upon contacts. Con-
tacts are based on statistical data and social studies; epidemiological parameters
are found in clinical studies and through calibration. RESULTS: Estimates say that
about 5% of the population fall sick with influenza every year in Austria. The model
shows clearly that this number is highly implausible under naive assumptions
because the epidemic would not behave like this; instead it would be much stron-
ger or die out – depending on the parameters. This reveals that our knowledge on
influenza is insufficient. Three additional assumptions might solve the problem:
First, that the influenza season highly depends on the seasonal climate, second,
that many people are generally resistant for the whole season and third, that many
people undergo infections without symptoms. Simulation of these assumptions
reveal three different possible propagations of the influenza that all result in 5%
sick people. CONCLUSIONS: The model cannot answer all questions about influ-
enza. But it is able to show clearly where we need more information and it provides
the possibility to test different assumptions and evaluate them. In other words, the
model can lead to a deeper understanding of the real world by examining assump-
tions that could not be observed directly so far.
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OBJECTVES: Pre-launch economic models are constructed to simulate long-term
changes in costs and effects. Typically Markov cohort models are used, whereas the
input often available to parameterize the models is obtained from cross-sectional,
annual, population data. The question is how to make the link and reconcile results
from long-term cohort models with annual observed population data? An illustra-
tion is given with modelled and observed hospitalisations due to rotavirus related
acute gastroenteritis. METHODS: The spread of hospitalisations of children up to
the age of 5 years, observed over a one -year period follows a normal distribution
(seasonality of the infection) with a peak around February March each year. The
assessment is done by 1-year age-groups (0 to 1y; 1 to 2y; 2 to 3y; 3 to 4y; 4 to 5y). The
parameters of this normal distribution are used to construct an overall modelled
population density curve with the same annual spread. Within this construction
the weekly spread of hospitalisations by age follows the density curve of the cohort
model with an age-specific Weibull distribution. To compare the model results
with the observation we analyse the age-group spread of hospitalisations but also
the results following the introduction of a specific intervention such as
vaccination. RESULTS: Pre-vaccination, the fit of the age-related spread of hospi-
talisations modelled using the population model to the observed data was compel-
ling (regression-scale model fit  0.05). Post-vaccination the modelled and ob-
served reduction in hospitalisations matched, however in the unvaccinated older
children the model predicted a lower reduction than observed which could be
explained by a herd protection effect in the observed population (indirect vaccine
benefit). Herd protection was not captured in the static model. CONCLUSIONS: It is
possible to make the link between cohort models and observed population data
provided the underlying model characteristics reflect reality.
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OBJECTIVES: Medical devices (MDs) play a major role in many aspects of health
care. The United States (US) and Europe (EU) categorise MDs into different classes,
with greatest regulatory control imposed on the highest risk Class III devices. In the
US, the Food and Drug Administration (FDA) approves Class-III MDs. In EU, the
European Commission sets the regulatory framework through which ‘notified bod-
ies’ confer a Confomité Européene (CE) mark for MDs. The purpose of this study
was to evaluate the extent to which patient-reported outcomes (PROs) are consid-
ered in the assessment of Class-III MDs in the US and EU. METHODS: The Drug
Approval Packages of MDs granted approval by the FDA from 2006-2011 were re-
viewed to identify MDs presenting PRO-related data. Ophthalmology MDs were
reviewed in greater detail to explore the range of PRO constructs presented. No
publically available database of EU MD approvals exists, making a parallel search
impossible. Instead, clinical trial databases (e.g. ClinicalTrials.gov) were searched
to identify EU-registered trials with PRO-endpoints for the ophthalmology MDs
identified from the US FDA review. RESULTS: The FDA approved 197 MDs from
2006-2011, of which 52(26.4%) presented PRO data. PRO-claims were lowest in 2008
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